Lower deep-breathing CVR-R predicts early oral semaglutide discontinuation in type 2 diabetes
Parasympathetic dysfunction assessed by deep-breathing CVR-R is associated with early discontinuation of oral semaglutide in type 2 diabetes: A multicenter retrospective study.
Abstract
Lower deep-breathing CVR-R (median 1.93%) predicted early oral semaglutide discontinuation in T2DM patients, with a cutoff of 2.55% stratifying persistence.
TitrateLab articles covering Semaglutide
Written by TitrateLab, separately from the study summarized above.
